cGP-PRo®    

cGP-PRo® is the first and only standardised cGP ingredient specifically developed for human health applications. Sourced from specially grown New Zealand blackcurrant cultivars high in cGP and combined with hydrolysed collagen, it is produced through a proprietary enzymatic process that ensures high concentrations of stabilised cGP.

This patent-protected ingredient is ideal for use in medicated foods, dietary supplements and functional foods & beverages. cGP-PRo® is designed to address some of the most significant health and wellness needs, including peripheral neuropathy, brain health, and healthy ageing.

Every batch of cGP-PRo® is rigorously tested by an independent, ISO-accredited laboratory to guarantee consistency, purity, and safety.

cGPMAX®

All cGPMAX® products contain our hero ingredient, cGP-PRo®. Some products also contain other research-backed ingredients such as Grapeseed extract and Bacopa extract.

Our customers from all corners of the world rely on cGPMAX® to support brain health, cardiovascular health and healthy ageing. In addition, we receive outstanding feedback of parents of children with specific neurodevelopmental conditions such as Rett Syndrome who use cGPMAX® to support improved quality of life.

Head to cgpmax.com to see the full range of science-backed cGPMAX® supplements. cGPMAX® supplements are available to purchase online and in select pharmacies and health stores across New Zealand.

cGPMAX-PLUS

The cGPMAX-PLUS range is available exclusively through registered practitioners in New Zealand and Australia. Offering the same science-backed formulations as the popular cGPMAX® supplements, the cGPMAX-PLUS range provides a higher dose for those requiring extra cGP support.

Available only through licensed practitioners. Please contact us at info@thecgplab.com to find out how to stock cGPMAX-PLUS in your practitioner practice.

SCROLL

Title

Doluptur, to velit doluptati doluptaspedi nones ea alique volute in cus. Te nobisci licimuscid ut lame quamus earcid quis rerunt poressundit lacessi nveniat.

Neuren Pharmaceuticals, Australia (1997-2007)
‍As a key scientist Dr Guan played a critical role in research & development in determining the neuroprotective eff ects of IGF-1 metabolite- GPE which ultimately led to the establishment of the fi rst university-based pharmaceutical company in New Zealand (NeuronZ Ltd, est. 1997). This was subsequently privatised in 2007 and is now known as Neuren Pharmaceuticals Ltd.She was contracted out through University of Auckland and working for Neuren Pharmaceuticals to lead a research team for developing several compounds for neurological conditions. One compound has gained FDA-approval for treating a developmental neurological condition, and another compound is undergoing clinical trials. She continued working with Neuren Pharmaceutical to provide consultancy services after resuming her appointment with the University of Auckland until the company moved to overseas

Slide 2
‍As a key scientist Dr Guan played a critical role in research & development in determining the neuroprotective eff ects of IGF-1 metabolite- GPE which ultimately led to the establishment of the fi rst university-based pharmaceutical company in New Zealand (NeuronZ Ltd, est. 1997). This was subsequently privatised in 2007 and is now known as Neuren Pharmaceuticals Ltd.She was contracted out through University of Auckland and working for Neuren Pharmaceuticals to lead a research team for developing several compounds for neurological conditions. One compound has gained FDA-approval for treating a developmental neurological condition, and another compound is undergoing clinical trials. She continued working with Neuren Pharmaceutical to provide consultancy services after resuming her appointment with the University of Auckland until the company moved to overseas

Slide 3
‍As a key scientist Dr Guan played a critical role in research & development in determining the neuroprotective eff ects of IGF-1 metabolite- GPE which ultimately led to the establishment of the fi rst university-based pharmaceutical company in New Zealand (NeuronZ Ltd, est. 1997). This was subsequently privatised in 2007 and is now known as Neuren Pharmaceuticals Ltd.She was contracted out through University of Auckland and working for Neuren Pharmaceuticals to lead a research team for developing several compounds for neurological conditions. One compound has gained FDA-approval for treating a developmental neurological condition, and another compound is undergoing clinical trials. She continued working with Neuren Pharmaceutical to provide consultancy services after resuming her appointment with the University of Auckland until the company moved to overseas

Slide 4
‍As a key scientist Dr Guan played a critical role in research & development in determining the neuroprotective eff ects of IGF-1 metabolite- GPE which ultimately led to the establishment of the fi rst university-based pharmaceutical company in New Zealand (NeuronZ Ltd, est. 1997). This was subsequently privatised in 2007 and is now known as Neuren Pharmaceuticals Ltd.She was contracted out through University of Auckland and working for Neuren Pharmaceuticals to lead a research team for developing several compounds for neurological conditions. One compound has gained FDA-approval for treating a developmental neurological condition, and another compound is undergoing clinical trials. She continued working with Neuren Pharmaceutical to provide consultancy services after resuming her appointment with the University of Auckland until the company moved to overseas

Slide 5
‍As a key scientist Dr Guan played a critical role in research & development in determining the neuroprotective eff ects of IGF-1 metabolite- GPE which ultimately led to the establishment of the fi rst university-based pharmaceutical company in New Zealand (NeuronZ Ltd, est. 1997). This was subsequently privatised in 2007 and is now known as Neuren Pharmaceuticals Ltd.She was contracted out through University of Auckland and working for Neuren Pharmaceuticals to lead a research team for developing several compounds for neurological conditions. One compound has gained FDA-approval for treating a developmental neurological condition, and another compound is undergoing clinical trials. She continued working with Neuren Pharmaceutical to provide consultancy services after resuming her appointment with the University of Auckland until the company moved to overseas

1997

2000

2008

2011

2023

HOMEDR JIAN GUANDR GUAN'S PUBLICATIONSOUR BRANDSPATENTSTHE SCIENCEcGP-PRoCONTACT

The cGP Lab Ltd, COPYRIGHT 2023